Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior Helicobacter pylori eradication therapy in gastric ulcer patients: A randomized prospective study

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 624-628

  Wada, Yoshihiro ^a   Ito, Masanori ^a   Takata, Shunsuke ^a   Kitamura, Shosuke ^a   Takamura, Akemi ^a   Tatsugami, Masana ^a   Imagawa, Shinobu ^a   Matsumoto, Yoshiaki ^a   Tanaka, Shinji ^b   Yoshihara, Masaharu ^c   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Atrophic gastritis; Eradication therapy; Gastroesophageal reflux disease (GERD); Helicobacter pylori; Proton pump inhibitor (PPI)

Indexed keywords

NIZATIDINE; RABEPRAZOLE; SOFALCONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOSCOPIC SURGERY; ERADICATION THERAPY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH CANCER; STOMACH ULCER; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CHALCONES; COHORT STUDIES; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; NIZATIDINE; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 67651205468     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Suzuki H, Hibi T, Marshall BJ: Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 2007; 42:1-15. (Pubitemid 46357245)
2. Gotoda T: Endoscopic resection of early gastric cancer. Gastric Cancer 2007; 10:1-11. (Pubitemid 46356261)
3. Gotoda T, Yamamoto H, Soetikno RM: Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41:929-942. (Pubitemid 44741406)
4. Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, Kajiyama G, Kawanishi M: High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14:729-735.
5. Kawanishi M: Development of reflux esophagitis following Helicobacter pylori eradication. J Gastroenterol 2005; 40:1024-1028. (Pubitemid 43055285)
6. Fossmark R, Johnsen G., Johanessen E, Waldum HL: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21:149-154. (Pubitemid 40222967)
7. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39:649-653. (Pubitemid 26426463)
8. Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3:87-97.
9. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston. Am J Surg Pathol 1996; 20:1161-1181.
10. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GNJ, Wallin L: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172-180. (Pubitemid 29333764)
11. Hoshihara Y: Endoscopic findings of GERD. Nippon Rinsho 2004; 62:1459-1464. (In Japanese with English abstract)
12. Carlsson R, Dent J, Bolling-Sternevald F, Johnsson F, Johnsson F, Junghard O, Lauritsen K, Riley S, Lundell L: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33:1023-1029. (Pubitemid 28505643)
13. Koike T, Ohara S, Sekine H, Iijima K, Kato K, Toyota T, Shimosegawa T: Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 2001; 15:813-820. (Pubitemid 32500427)
14. Gillen D, Wirz AA, Ardill JE, McColl KEL: Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116:239-247. (Pubitemid 29055344)
15. Gillen D, Wirz AA, McColl KEL: Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004; 126:980-988. (Pubitemid 38451169)
16. Bell N, Karol MD, Sachs G, Greski-rose P, Jennings DE, Hunt RH: Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther 2001; 15:105-113. (Pubitemid 32055590)
17. Hamamoto N, Hashimoto T, Adachi K, Hirakawa K, Ishihara S, Inoue H, Taniura H, Niigaki M, Sato S, Kushiyama Y, Suetsugu H, Miyake T, Kinoshita Y: Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. J Gastroenterol Hepatol 2005; 20:281-286. (Pubitemid 40343282)
18. Isomoto H, Furusu H, Ohnita K, Wen CY, Inoue K, Kohno S: Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin, and clarithromycin. World J Gastroenterol 2005; 11:1629-2163 (Pubitemid 40520802)